2616 — CStone Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- HK$13.80bn
- HK$13.15bn
- CNY269.58m
Annual income statement for CStone Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 244 | 481 | 464 | 407 | 270 |
| Cost of Revenue | |||||
| Gross Profit | 137 | 278 | 304 | 240 | 51.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,162 | 1,376 | 819 | 483 | 680 |
| Operating Profit | -1,918 | -894 | -355 | -76 | -411 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,920 | -903 | -367 | -91.2 | -424 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,920 | -903 | -367 | -91.2 | -437 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,920 | -903 | -367 | -91.2 | -437 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1,920 | -903 | -367 | -91.2 | -437 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.65 | -0.75 | -0.411 | -0.063 | -0.306 |